The empagliflozin/linagliptin combination is considered as a promising adjunct treatment option for patients with inadequate glycemic control on metformin. This combination therapy modestly reduces body weight and blood pressure without significant safety issues.1 Boehringer Ingelheim India and Docplexus have organized a webinar on 31st October 2020 from 03:00 PM IST onwards. In this webinar, Prof.
Mark E Cooper will elucidate on the Expanding Treatment Options for Patients with Type 2 Diabetes: The Role of Empagliflozin+Linagliptin combination. We invite you to share your questions which will be answered by the expert at the end of the session.